Comparative Pharmacology
Head-to-head clinical analysis: DYAZIDE versus HYDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYAZIDE versus HYDROFLUMETHIAZIDE.
DYAZIDE vs HYDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
None Documented
None Documented
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateTriamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Terminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."